GH Research price target lowered to $35 from $40 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on GH Research (GHRS) to $35 from $40 and keeps a Buy rating on the shares. Competitive momentum in short-acting psychedelics, led by advancing programs such as Atai Beckley’s (ATAI) BPL-003 and AbbVie’s (ABBV) GM-2505, combined with the ongoing FDA hold, led the firm to fine-tune its expected GH001 launch timing and peak share in treatment-resistant depression, resulting in a revised price target. However, it continues to view GH001 as a leading asset within the short-duration psychedelics space and notes that its revised target still represents “robust upside potential.”